Cita APA

Sánchez Rovira, P., Lindén Hirschberg, A., Gil Gil, M., Bermejo de las Heras, B., & Nieto Magro, C. (2020). A Phase II Prospective, Randomized, Double‐Blind , Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor–Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting.

Citación estilo Chicago

Sánchez Rovira, Pedro, Angelica Lindén Hirschberg, Miguel Gil Gil, Begoña Bermejo de las Heras, y Concepción Nieto Magro. A Phase II Prospective, Randomized, Double‐Blind , Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor–Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting. 2020.

Cita MLA

Sánchez Rovira, Pedro, et al. A Phase II Prospective, Randomized, Double‐Blind , Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor–Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting. 2020.